A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)

Stefania Bellone, Dana M. Roque, Eric R. Siegel, Natália Buza, Pei Hui, Elena Bonazzoli, Adele Guglielmi, Luca Zammataro, Nupur Nagarkatti, Samir Zaidi, J. Lee, Dan‐Arin Silasi, Gloria S. Huang, Vaagn Andikyan, Shari Damast, Mitchell Clark, Masoud Azodi, Peter E. Schwartz, Joan Tymon‐Rosario, Justin Harold, Dennis Mauricio, Burak Zeybek, Gulden Menderes, Gary Altwerger, Elena Ratner, Ludmil B. Alexandrov, Akiko Iwasaki, Yong Kong, Eric Song, Weilai Dong, Julia A. Elvin, Jungmin Choi, Alessandro D. Santin